Corbus Pharmaceuticals Holdings (CRBP) Income towards Parent Company (2013 - 2025)

Corbus Pharmaceuticals Holdings' Income towards Parent Company history runs 13 years deep, the most recent figure standing at $1.1 million for Q3 2025.

• In Q3 2025, Income towards Parent Company fell 26.08% year-over-year to $1.1 million; the TTM figure through Dec 2025 stood at -$37.8 million (down 951.59% YoY), while the FY2024 annual figure was $4.4 million, up 109.07% from the prior year.
• Income towards Parent Company was $1.1 million for Q3 2025 at Corbus Pharmaceuticals Holdings, up from -$19.2 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $1.8 million in Q4 2024 to a low of -$19.8 million in Q1 2025.
• Historically, Income towards Parent Company has averaged -$9.3 million across 5 years, with a median of -$10.5 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Income towards Parent Company surged 116.13% in 2024, then slumped 10562.96% in 2025.
• A 5-year view of Income towards Parent Company shows it stood at -$10.0 million in 2021, then retreated by 7.99% to -$10.8 million in 2022, then declined by 2.2% to -$11.0 million in 2023, then soared by 116.13% to $1.8 million in 2024, then plunged by 36.8% to $1.1 million in 2025.
• The last three Income towards Parent Company figures came in at $1.1 million (Q3 2025), -$19.2 million (Q2 2025), and -$19.8 million (Q1 2025), per Business Quant data.